Neue Therapieoptionen bei Autoimmunerkrankungen

Die Pharmakotherapie rheumatischer und anderer entzündlicher Erkrankungen hat sich seit der Einführung der Biologika wesentlich gewandelt. Etanercept und weitere Biologika zählen heute zu den erfolgreichsten Innovationen und bieten neben einem günstigen Nutzen-Risiko-Verhältnis auch die realistische Aussicht auf eine Remission. Dieser Beitrag stellt neueste Entwicklungen bei den Biologika, Biosimilars und den Small Molecules vor.

Schlüsselwörter

Autoimmunerkrankungen - Biologika - Biosimilars - JAK-Inhibitoren

• Literatur

• 1 Beukelman T, Haynes K, Curtis JR. et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 1263-1271
• 2 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637-1646
• 3 Lovell DJ, Reiff A, Ilowite NT. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504
• 4 Horneff G, Schmeling H, Biedermann T. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-1644
• 5 Horneff G, De Bock F, Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-525
• 6 Horneff G, Burgos-Vargas R, Constantin T. et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: phase 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014; 73: 1114-1122
• 7 Horneff G, Foeldvari I, Minden K. et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol 2015; 67: 2240-2249
• 8 Lovell DJ, Ruperto N, Goodman S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-820
• 9 Burgos-Vargas R, Tse SM, Horneff G. et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2015; 67: 1503-1511
• 10 Hyams JS, Griffiths A, Markowitz J. et al. Safety and efficacy of adalimumab for moderate to severe Crohnʼs disease in children. Gastroenterology 2012; 143: 365-374
• 11 Horneff G, Seyger MMB, Arikan D. et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohnʼs disease. J Pediatr 2018; 75: 265
• 12 Brunner HI, Ruperto N, Tzaribachev N. et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 2018; 77: 21-29
• 13 Hyams J, Crandall W, Kugathasan S. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohnʼs disease in children. Gastroenterology 2007; 132: 863-873
• 14 Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-522
• 15 Ruperto N, Lovell DJ, Cuttica R. et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 718-722
• 16 Ruperto N, Brunner HI, Quartier P. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-2406
• 17 De Benedetti F, Brunner HI, Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-2395
• 18 Brunner HI, Ruperto N, Zuber Z. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110-1117
• 19 Genovese MC, Fleischmann R, Kivitz AJ. et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015; 67: 1424-1437
• 20 European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (May 2014).. Im Internet: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf Stand: 02.03.2018
• 21 Statista. Patentausläufe umsatzstarker Biopharmazeutika in den USA und der EU im Zeitraum der Jahre von 2013 bis 2019. Im Internet: https://de.statista.com/statistik/daten/studie/372113/umfrage/patentauslaeufe-umsatzstarker-biopharmazeutika-in-den-usa-und-der-eu/ Stand: 05.03.2018
• 22 Kremer JM, Bloom BJ, Breedveld FC. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase II a trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905